European Association for the Study of Diabetes (EASD) 

Presentation of the positive results of a study on TOTUM-63 carried out by the CarMeN laboratory in Lyon.

Read the press release

VALEDIA®

VALBIOTIS announces positive results from the Phase IIA clinical study of VALEDIA®.

Read the press release

VALEDIA®

VALBIOTIS succeeds in the industrial production of VALEDIA®, a major scientific innovation for prediabetic people, in collaboration with the Pierre Fabre group.

Read the press release

Prediabetes

VALBIOTIS publishes the first prediabetes market data.

Read the press release
S c r o l l

Products

.01

Pipeline

4 products in clinical development

Learn more

.02

VALEDIA® – Prediabetes

Prediabetes
• Reduction of the risk of type 2 diabetes
• Positive Phase IIA clinical study

Learn more

.03

LpD64

Overweight and /or obesity
• Modulation of intestinal microbiota
• Clinical Phase I/II positive

Learn more

.04

VAL-070

Mild to moderate hypercholesterolemia
• Reduction of blood LDL-cholesterol
• Clinical Phase I/II positive

Learn more

.05

TOTUM-63 – Non-alcoholic hepatic steatosis

Non-alcoholic hepatic steatosis
• Reduction of steatosis, risk factor for NASH
• Clinical Phase I/II positive

Learn more

Key figures

Patent families filed

4
All exploitation rights obtained

Employees

> 35
75% in R&D

Listed on the Stock Exchange

2017
Euronext Growth

Our last posts

16.09.2019

Annual Meeting of the European Association for the Study of Diabetes (EASD)

En savoir plus
10.09.2019

Seminar Biotech Portzamparc, Paris (France)

En savoir plus
24.06.2019

Health Tech Investors Day 2019

En savoir plus
07.06.2019

79th scientific sessions of American Diabetes Association

En savoir plus
Voir tous

VALBIOTIS© listed on the Stock Exchange

Investors

Follow us!